[8-K] NEUROCRINE BIOSCIENCES INC Reports Material Event

Rhea-AI Filing Summary

Neurocrine Biosciences, Inc. (NBIX) reported an update to its senior leadership arrangements. Former Chief Medical Officer Eiry W. Roberts, M.D., who transitioned to the role of Strategic Advisor effective June 2, 2025, will continue in that advisory role for an additional 12 months. On November 21, 2025, the company and Dr. Roberts entered into an amendment to her amended and restated employment agreement to extend her employment term through December 31, 2026.

The amendment is filed as an exhibit to this report, reflecting the company’s decision to retain Dr. Roberts’ expertise in a strategic advisory capacity following the appointment of Sanjay Keswani, M.D. as Chief Medical Officer.

false000091447500009144752025-11-212025-11-21

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 21, 2025

NEUROCRINE BIOSCIENCES, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			0-22705			33-0525145
(State or Other Jurisdiction			(Commission			(IRS Employer
of Incorporation)			File Number)			Identification No.)
6027 Edgewood Bend Court
San Diego,			California			92130
(Address of Principal Executive Offices)						(Zip Code)

(858) 617-7600

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol						Name of each exchange on which registered
Common Stock, $0.001 par value			NBIX						Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02.    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e) As previously disclosed, Sanjay Keswani, M.D. succeeded Eiry W. Roberts, M.D. as the Chief Medical Officer of Neurocrine Biosciences, Inc. (the “Company”), effective June 2, 2025. In connection with this transition, the Company and Dr. Roberts entered into an Amended and Restated Employment Agreement, effective as of June 2, 2025 (the “Amended Employment Agreement”), pursuant to which she serves as Strategic Advisor through December 31, 2025.

On November 21, 2025, the Company entered into an amendment to the Amended Employment Agreement (the “Amendment”) to extend the term of employment for an additional 12-month period, expiring on December 31, 2026.

The foregoing is only a brief description of certain terms of the Amendment, does not purport to be complete, and is qualified in its entirety by reference to the full text of the Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K.

Item 9.01.    Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
10.1						Amendment to Amended and Restated Employment Agreement dated November 21, 2025 between the Company and Eiry W. Roberts, M.D.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			NEUROCRINE BIOSCIENCES, INC.
Dated: November 24, 2025			/s/ Darin M. Lippoldt
			Darin M. Lippoldt
			Chief Legal Officer

FAQ

What did Neurocrine Biosciences (NBIX) announce in this 8-K filing?

Neurocrine Biosciences announced an amendment to the employment agreement of Eiry W. Roberts, M.D., extending her term as Strategic Advisor for an additional 12 months, through December 31, 2026.

What is Eiry W. Roberts, M.D.’s current role at Neurocrine Biosciences (NBIX)?

Eiry W. Roberts, M.D. serves as a Strategic Advisor to Neurocrine Biosciences under an amended and restated employment agreement.

When does the extended employment term for Eiry W. Roberts, M.D. end?

The amended employment term for Eiry W. Roberts, M.D. now expires on December 31, 2026.

When did Neurocrine Biosciences enter into the amendment to the employment agreement?

The company entered into the amendment with Eiry W. Roberts, M.D. on November 21, 2025.

Who is the current Chief Medical Officer of Neurocrine Biosciences (NBIX)?

Sanjay Keswani, M.D. succeeded Eiry W. Roberts, M.D. as Chief Medical Officer, effective June 2, 2025.

Where can investors find the full terms of the amended employment agreement for Eiry W. Roberts, M.D.?

The full text of the amendment to the amended and restated employment agreement is filed as Exhibit 10.1 to this report.